Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the patent application for Oncoral has been approved in Japan. The approval in Japan adds to the already obtained patents in the US and a selected number of countries in Europe and China. The patent secures the intellectual property protection rights for Oncoral until year 2035 plus potential patent extension. 

“We are very pleased to also have the patent for Oncoral approved in Japan as the unmet medical needs for gastric cancer treatment in Japan are significant. More than 115,000 Japanese were diagnosed with gastric cancer in 2018 and the incidence rate is around five times higher than US and Europe, so the need for improved treatment options for these patients is great”, said Carl Bjartmar, MD, PhD, Chief Medical Officer at Ascelia Pharma.

Press inquiries should be adressed to: